SAFETY AND TOLERANCE OF VPA-985 FOR PATIENTS WITH CONGESTIVE HEART FAILURE

VPA-985 对充血性心力衰竭患者的安全性和耐受性

• 批准号: 6275377
• 负责人: WILLIAM T ABRAHAM
• 金额: $ 3.14万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275377
• 关键词: cardiovascular disorder chemotherapy; clinical research; clinical trials; congestive heart failure; drug screening /evaluation; drug tolerance; human subject; human therapy evaluation; kidney function; neurohormones; oral administration; vasopressins

VPA-985 is a nonpeptid, orally active competitive vasopressin receptor antagonist, specific for the v2 receptor subtype. This study is designed to valuate the safety and tolerance of single oral doses of vpa-985 in patients with symptomatic heart failure (nyha classes II and III). In addition, preliminary pharmacokinetics and pharmacodynamic assessments will be collected.

VPA-985是一种非肽类口服活性竞争性血管加压素受体 拮抗剂，特异性针对V2受体亚型。 本研究设计 评价单次口服vpa-985的安全性和耐受性， 有症状的心力衰竭患者（NYHA II和III级）。 在 此外，初步药代动力学和药效学评估 将被收集。